2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 94

Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Abstract Number: 2473

Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis
Abstract Number: 2887

Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses’ Health Study
Abstract Number: 2708

Post-Occlusive Reactive Hyperemia (PORH) Test Mirrors Vascular Changes in Systemic Sclerosis (SSc):a Laser Speckle Contrast (LASCA) Study
Abstract Number: 752

Potential Roles of Toll-like Receptor 4 in the Murine Models of Systemic Sclerosis
Abstract Number: 2214

Power Doppler Ultrasonography for Detection of Abnormal Fascial Vascularity: A Potential Early Diagnostic Tool in Fasciitis of Dermatomyositis
Abstract Number: 1350

Practice What You Preach? Suboptimal Guideline Adherence By Rheumatologists in Patients with Rheumatoid Arthritis
Abstract Number: 1279

Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients
Abstract Number: 193

Pre-Operative Pain and Function: Profiles of Patients Selected for Total Knee Replacement Among Surgeons in the United States
Abstract Number: 2530

PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors
Abstract Number: 2930

Precisely Quantified Fibrosis in Labial Salivary Glands Predicts Sjögren’s Syndrome Classification in a Multiple Regression Model
Abstract Number: 742

Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer
Abstract Number: 1500

Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
Abstract Number: 1495

Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Abstract Number: 1421

Preclinical Interstitial Lung Disease in Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].